Advanced Search

 

Study ID Status Title Patient Level Data
TRX105848 Completed An Open Label, Single Dose, Parallel Group Study to Evaluate Absorption and Transit Characteristics of TREXIMA and RELPAX in Patients Inside and Outside of an Acute Migraine Attack. Study Listed on ClinicalStudyDataRequest.com
TRX105850 Completed A randomized, double-blind, single migraine attack, placebo -controlled, patallel-group multicenter study to evaluate the efficacy and tolerability or Trexima (sumatriptan succinate/naproxen sodium) tablets vs placebo when administered during the mild pain phase of menstrual migraine in women with dysmenorrhea Study Listed on ClinicalStudyDataRequest.com
TRX105852 Completed A randomized, double-blind, single migraine attack, placebo-controlled, parallel-group multicenter study to evaluate the efficacy and tolerability of Trexima (sumatriptan succinate.naproxen sodium) tablets vs placebo when administered during the mild pain phase of menstrual migraine in women with dysmenorrhea Study Listed on ClinicalStudyDataRequest.com
TRX106571 Completed A Study of Combination Product (sumatriptan succinate and naproxen sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2) Study Listed on ClinicalStudyDataRequest.com
TRX106573 Completed A Study of Combination Product (sumatriptan succinate and naproxen sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2) Study Listed on ClinicalStudyDataRequest.com
TRX109011 Completed A Randomized, Double-blind, Double-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of TREXIMET® (Sumatriptan + Naproxen Sodium) vs. Butalbital-containing Combination Medications for the Acute Treatment of Migraine when administered during the Moderate-Severe Migraine Pain, 1 of 2 Study Listed on ClinicalStudyDataRequest.com
TRX109013 Completed A Crossover, Randomized, Double-blind, Double-dummy, Placebo-controlled Study to Evaluate the Efficacy of TREXIMET®/Sumatriptan + Naproxen Sodium vs. Butalbital-containing Combination Medications for the Acute Treatment of Migraine when administered during Moderate-Severe Migraine Pain, 2 of 2 Study Listed on ClinicalStudyDataRequest.com
TXA107563 Completed A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and tolerability of TREXIMA* (sumatriptan succinate/naproxen sodium) for a single moderate or severe headache in adults diagnosed with probable migraine without aura (ICHD-II 1.6.1) (*TREXIMET) Study Listed on ClinicalStudyDataRequest.com
TXA107977 Completed Study TXA107977, a Long-Term Safety Study of a Combination Product Containing Sumatriptan Succinate and Naproxen Sodium for the Treatment of Migraine in Adolescents Study Listed on ClinicalStudyDataRequest.com
USA107212 Terminated A randomized open-label multicenter parallel-group study to compare the efficacy safety and resource utilization of a remifen-tanil/propofol analgesia/sedation regimen versus a sufen-tanil/propofol analgesia/sedation regimen in mechanically venti-lated intensive care patients requiring analgesia and sedation for up to 7 days
V7341104 Completed A Dose-Ranging Study to Evaluate the Pharmacokinetics and Pharmacodynamics of a Sleep Aid
VEG10004 Completed An Open-Label, Two-Part Study to Characterize the Pharmacokinetics of a Single Intravenous Dose of Pazopanib (GW786034) and the Absorption, Distribution, Metabolism and Elimination of a Single Oral [14C] Labeled Dose of Pazopanib in Subjects with Solid Tumor Malignancies
VEG10005 Completed An Open-Label, Two-Period, Randomized, Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of Single Doses of Pazopanib in Cancer Patients
VEG10006 Completed An Open-Label, Safety, Pharmacokinetic and Pharmacodynamic Study of Multiple Doses of GW786034 and Lapatinib Concomitantly Administered in Cancer Patients.
VEG10007 Completed A Multi-center, Open-Label, Multiple-probe Drug Interaction Study to Determine the Effects of GW786034 on the Metabolism of Cytochrome P450 Probe Drugs in Patients with Solid Tumors
VEG102616 Completed A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects with Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma
VEG102857 Completed Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma
VEG105192 Completed A Randomised, Double-blind, Placebo controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients with Locally Advanced and/or Metastatic Renal Cell Carcinoma
VEG105281 Completed A Phase II, Open-Label, Randomized, Multicenter Trial of Pazopanib (GW786034) in Combination with Lapatinib (GW572016) Compared to Pazopanib Monotherapy and Lapatinib Monotherapy in Subjects with FIGO Stage IVB or Recurrent or Persistent Cervical Cancer with Zero or One Prior Chemotherapy Regimen
VEG105290 Completed A Phase II Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Pazopanib (GW786034) as Neoadjuvant Therapy in Treatment-Naïve Subjects with Stage IA, IB, IIA or IIB (to T2) Resectable Non-Small Cell Lung Cancer (NSCLC)
VEG105424 Completed An Open-Label, Pharmacokinetic Study of the Safety and Tolerability of Pazopanib in Combination with FOLFOX 6 or CapeOx in Subjects with Colorectal Cancer
VEG105427 Completed A Phase I, Open-Label, Study of the Safety, Tolerability and Pharmacokinetics of Pazopanib in Combination with Paclitaxel on a Weekly Schedule for 3 Consecutive Wks, Paclitaxel & Carboplatin on an Every 21 Days Schedule and Lapatinib & Paclitaxel on a Weekly Schedule for 3 Consecutive Weeks
VEG105430 Active, Not Recruiting An Open-Label, Phase Ib Study to Assess the Long Term Safety Profile of Pazopanib in Cancer Patients
VEG107200 Completed A Phase I, Open-Label, Dose-Escalation, Multi-Center Study or Pazopanib (GW786034) in Adult Patients with Hepatocellular Cancer
VEG107769 Completed An open-label extension study to assess the safety and efficacy of pazopanib in subjects with renal cell carcinoma previously enrolled on protocol VEG105192

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.